


Innovation, Investment, Infrastructures: the view from DG RTD




European Commission
Directorate-General for Research
Directorate F – Health
Ruxandra Draghia-Akli, MD, PhD –
Director

Health related research
infrastructures and their
contribution to the EU's grand
challenges

26 October 2010 Brussels



Early infrastructures and the benefits of collaboration...



Early microscope

me -- Draghia-Akli 341 -- bmj.com - Windows Internet Explorer

com/content/341/bmj.c5016.full

ols Help

Future -- Draghia-Akli 341 -- bmj....

Research **FREE** Education News Comment Topics Video Archive About

Archive > BMJ 2010; 341:c5016 doi:10.1136/bmj.c5016 (Published 22 September 2010)

icle

ct **Free**

ext **Free**

of print issue

ices

il to friend

me when this

e is cited

me if a correction

sted

me when rapid

ponses are

ished

lar articles in this

al

lar articles in

ed

article to my folders

load to citation

ager

est permissions

id Responses

mit a rapid

onse

apid responses

ished

gle Scholar

Med

ted Content

s: cardiovascular

em

unology (including

gy)

sity (nutrition)

etes

th education

ial bookmarking

BMJ 2010;341:c5016 doi:10.1136/bmj.c5016 (Published 22 September 2010)

Cite this as: BMJ 2010;341:c5016

Letter

Lost without translation

EC's science-friendly future

Ruxandra Draghia-Akli, director, health research¹

Author Affiliations

Ruxandra.Draghia-Akli@ec.europa.eu

Watts describes research funders' increasing emphasis on translational research and cites the European Commission's seventh framework programme as an example.¹ On 19 July 2010 my colleagues and I announced the publication of our 2011 work programme and its corresponding calls for research proposals. The work programme has a budget of €681 m and spans the continuum from basic to translational research. The deadlines for submitting proposals through the online application system are 13 October and 20 November 2010, dependent on application type.

Eight of the 51 topics aim at supporting clinical trials to verify the safety and efficacy of various treatments and to promote the translation of research into clinical practice, each of which may result in several projects receiving up to €6m. Successful projects will target results increasing therapeutic options for patients and stimulate the implementation of best practice in member states. Topics address issues as diverse as regenerative medicine, brain related diseases, human development and ageing, antimicrobial drug resistance, cancer, cardiovascular diseases, diabetes and obesity, and off-patent medicines for children.

Ten further topics require that at least 15% or 30% of the EU grant is allocated to small and medium sized enterprises. Two of them will support ambitious high impact research initiatives in immunisation and in epi-genomics with up to €30m of EU funding.

More information is available at <http://cordis.europa.eu/fp7/health/>

Notes

Cite this as: BMJ 2010;341:c5016

Footnotes

Competing interests: None declared

What's

- Last 7
- Past v
- Currei
- Rapid

Blo

- Anna C paper - their ne
- Richar priorit
- Richar review,
- Helen . policy r (22 Oc
- James its pos diseas

Keep up

iGoogl

iGoogl

twitter

iGoogl

Service:

- Subm
- Subsc
- Requ

Tools

Insofar as scientific discoveries have been finding their way into clinical practice for two centuries, and will continue to do so, it's self evident that translation (by whatever name) happens, and will go on happening.

The point now at issue is how far the biomedical research community can take firmer control of the process. How far it can be speeded up and given direction.

How far it will be possible, years from now, to be certain that without all the current effort, this drug or that diagnostic would still be a mere speculation in *Nature* or *Science*—lost without translation.

BMJ 2010;341:c4363

It is clear that infrastructures are crucial to facilitating the process of translation....

...and that the EU can 'take control of the process' by providing funding for research infrastructures, and funding for scientists to exploit the opportunities they present



Clinical trials coordination/ policy analysis



European Clinical Research Infrastructures Network

Designed to integrate clinical research in Europe through the interconnection of national networks of clinical research centres and clinical trial units and to develop services to provide support for **multicentre clinical studies in Europe** (13 countries: Austria, Belgium, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Spain, Sweden, Switzerland, United Kingdom).



Impact on Clinical Research of European legislation

One-year FP7 project (2008)

Aim was to measure and analyse the direct and indirect impact of the CTD 2001/20/EC and related legislations in the EU on all categories of clinical research and on the different stakeholders: commercial and non-commercial sponsors, ethics committees and competent authorities.

Delivered input to the discussions about the regulatory framework for the conduct of clinical trials in Europe.



Project Acronym	Project Title	Project EC Contribution
ICREL	Impact on Clinical Research of European Legislation	348.600,00
EUROSTEMCELL	European Consortium for Communicating Stem Cell Research	830.238,00
TRANSEURO	Neural Transplantation In The Treatment Of Patients With Parkinson's Disease	11.994.095,00
IMPACTT	Immunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatment	5.876.724,00

FP7 Health Programme objectives:

- Improving health of European citizens
- Increasing competitiveness of European health-related industries and businesses
- Addressing global health issues

Funding for translational and clinical research reinforced in recent years

- Largest part of the FP7 Health Theme is dedicated to translational research in major diseases
- 2011 call published on 19 July 2010 has a major focus on Investigator-Driven Clinical Trials (IDCT)
- Clarifications on financing in an explanatory memorandum also published
- Focus on IDCT will continue in the remaining calls of FP7

Research priorities: highlights for the immediate future Work Programme 2011

- SME-dedicated topics
 - 15% contribution by end of FP7 i.e. €900M
- Supporting clinical trials to verify safety and efficacy
- High impact topics in epi-genomics and vaccinology/immunology
- *2012-13: brain, diabetes, lifestyle induced conditions, medical technologies, personalised medicines, health care systems, promotion & prevention ...*

Focus on investigator-driven clinical trials (IDCT)

- 2.2.1-1 IDCT for childhood-onset neurodegenerative diseases
- 2.2.2-1 IDCT for therapeutic interventions in elderly populations
- 2.3.1-1 IDCT of off-patent antibiotics
- 2.4.1-1 Investigator-driven treatment trials for rare cancers
- 2.4.2-1 IDCT for the management of cardiovascular diseases
- 2.4.3-1 IDCT to reduce diabetes complications
- 4.2-1 IDCT on off-Patent medicines for children

Also

- 1.4-1 Regenerative medicine clinical trials
- 4.2-2 Adverse drug reaction research


Other activities...

Commission workshop: “Can We Facilitate IDCT?”

- 10 November 2009 in Brussels
- Small group of high-level representatives from academia, industry, EU Commission (DGs Research, Health and Consumers, and Enterprise and Industry), national regulators, European Medicines Agency, insurance industry

Presentations and report available at:

http://ec.europa.eu/research/health/medical-research/clinical-trials/idct-workshop_en.html



Has demonstrated the need to adapt rules to promote international clinical trials.



Involvement of patients in clinical trials



Patient Partner project
Funded under FP7

Patient Partner final workshop will be held on December 7th and 8th 2010 in Brussels


<http://patientpartner-europe.eu/>



Value+ project coordinated by the European Patient Forum;
Funded under the Public Health Programme of the Health and Consumers DG

<http://www.eu-patient.eu/Initatives-Policy/Projects/ValuePlus/>





© Geluck 2008